Welcome to our dedicated page for NYXOAH S A SEC filings (Ticker: NYXH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nyxoah SA filings document the company's foreign-private-issuer reporting for its medical-technology business and the Genio system for obstructive sleep apnea. Form 6-K reports furnish quarterly and annual operating results, press releases, manufacturing-capacity updates, clinical and regulatory disclosures, and information incorporated by reference into registration statements on Form S-8 and Form F-3.
The filing record also covers capital-structure and governance matters, including ordinary-share offerings, underwriting agreements, shareholder voting matters, transparency-related ownership information, material-event reports, and exhibits that describe financing terms and public-company obligations.
Nyxoah SA reported strong revenue growth and detailed governance items in its latest update. First quarter 2026 revenue rose to €6.4 million, up from €1.1 million a year earlier, driven mainly by U.S. Genio system commercialization and continued international sales. Gross margin was 57% on cost of goods sold of €2.7 million. Operating loss remained high at €20.5 million, with a net loss of €15.9 million, reflecting heavy R&D and U.S. commercial spending. Cash, cash equivalents and financial assets totaled €25.9 million as of March 31, 2026, and management highlights significant doubt about the company’s ability to continue as a going concern without additional funding.
The company will hold its annual shareholders’ meeting on June 10, 2026, immediately followed by an extraordinary meeting to renew authorized capital, ratify change‑of‑control protection in its convertible bonds and reappoint or appoint several directors, including one new independent director.
Nyxoah SA reported strong revenue growth in 2025 as it began full commercial activity in the U.S. for its Genio system. Net revenue rose to €10.0 million from €4.5 million in 2024, driven mainly by the U.S. launch after FDA approval.
Despite higher sales, the company remained deeply loss-making, with a full-year operating loss of €83.5 million and a net loss of €90.1 million, reflecting heavy spending on research, clinical programs and U.S. commercial build-out. Cash, cash equivalents and financial assets totaled €48.0 million at December 31, 2025.
Nyxoah also updated its capital structure, disclosing 43,662,403 voting shares outstanding and 225 convertible bonds, and reported transparency notifications showing Robert Taub and related entities holding 9.99% of voting rights and BNP Paribas Asset Management Europe SAS holding 3.00%.
Nyxoah SA furnished a report highlighting preliminary, unaudited financial and operating results for the fourth quarter and full year 2025 and providing revenue guidance commentary for the first quarter of 2026. The Company’s first full quarter of U.S. commercialization after FDA approval generated what management describes as strong momentum, with early U.S. patients seeing positive outcomes, a waiting list for additional surgeon training, and patients already scheduled for implants.
Management stated that global revenue exceeded €10 million, supported by the U.S. launch and continued international expansion. Nyxoah also noted it will present at the 44th Annual J.P. Morgan Healthcare Conference, offering investors an opportunity to hear more about its commercialization progress and outlook.
Nyxoah SA is offering 1,215,964 ordinary shares at $4.6304 (€4.00) per share, raising gross proceeds of about $5.6 million and estimated net proceeds of $5.5 million (€4.8 million). The shares are sold directly to investors without an underwriter, and trade on Nasdaq and Euronext Brussels under “NYXH.” Nyxoah plans to use the cash to support the U.S. launch and international commercialization of its Genio system for obstructive sleep apnea, fund clinical data generation and physician-led studies, advance R&D, build a pipeline in OSA monitoring and diagnostics, and for general corporate purposes.
Alongside this deal, the company has arranged a €17.0 million private placement of 4,265,714 ordinary shares at €4.00 and a separate offering of up to €45.0 million in amortizing senior unsecured convertible notes, expected to yield about €41.4 million in gross proceeds. As of September 30, 2025, Nyxoah had 37,544,782 ordinary shares outstanding, which would increase to 38,760,746 after this offering, before giving effect to the private placement, notes conversion, or warrant exercises.
Nyxoah SA announced a multi-part financing to support commercialization of its Genio system and ongoing R&D. The company agreed to a private placement of ordinary shares at €4.00 per share for aggregate gross proceeds of approximately €17.0 million, expected to close on or about November 18, 2025, subject to customary conditions.
Separately, Nyxoah entered a registered direct offering of ordinary shares at U.S.$4.6304 per share for aggregate gross proceeds of approximately U.S.$5.6 million, also expected to close on or about November 18, 2025. In addition, the company signed a convertible notes deal for up to €45.0 million aggregate principal amount at an 8.0% original issue discount, issued in two €22.5 million tranches; assuming both tranches, gross proceeds total approximately €41.4 million. The notes bear 6.5% interest, mature three years from issuance, and amortize quarterly over 12 installments, with optional share-settled payments priced per the bond instrument. Initial conversion pricing is set at 125% of the private placement price for the first tranche.
Proceeds across the transactions are designated for U.S. and ex-U.S. commercialization, clinical data, R&D and cost reductions, pipeline and collaborations, and general corporate purposes.
Nyxoah SA announced a multi-part financing to support commercialization of its Genio system and ongoing R&D. The company agreed to a private placement of ordinary shares at €4.00 per share for aggregate gross proceeds of approximately €17.0 million, expected to close on or about November 18, 2025, subject to customary conditions.
Separately, Nyxoah entered a registered direct offering of ordinary shares at U.S.$4.6304 per share for aggregate gross proceeds of approximately U.S.$5.6 million, also expected to close on or about November 18, 2025. In addition, the company signed a convertible notes deal for up to €45.0 million aggregate principal amount at an 8.0% original issue discount, issued in two €22.5 million tranches; assuming both tranches, gross proceeds total approximately €41.4 million. The notes bear 6.5% interest, mature three years from issuance, and amortize quarterly over 12 installments, with optional share-settled payments priced per the bond instrument. Initial conversion pricing is set at 125% of the private placement price for the first tranche.
Proceeds across the transactions are designated for U.S. and ex-U.S. commercialization, clinical data, R&D and cost reductions, pipeline and collaborations, and general corporate purposes.
Nyxoah furnished a Form 6-K stating that on November 13, 2025 it announced its unaudited third quarter 2025 results. Those results are contained in a Third Quarter 2025 report attached as Exhibit 99.1. The company also states that the information in Exhibit 99.1 is incorporated by reference into its existing registration statements on Form S-8 and Form F-3, so that these offerings will automatically reflect the latest disclosed information.
Nyxoah furnished a Form 6-K stating that on November 13, 2025 it announced its unaudited third quarter 2025 results. Those results are contained in a Third Quarter 2025 report attached as Exhibit 99.1. The company also states that the information in Exhibit 99.1 is incorporated by reference into its existing registration statements on Form S-8 and Form F-3, so that these offerings will automatically reflect the latest disclosed information.
Nyxoah SA submitted a Form 6-K as a foreign private issuer to furnish a company press release. The filing states that on September 23, 2025, Nyxoah issued a press release, which is attached as Exhibit 99.1. The exhibit is being furnished rather than filed, meaning it is not subject to Section 18 liability and is not automatically incorporated into other Securities Act or Exchange Act filings unless specifically referenced.
Nyxoah SA submitted a Form 6-K as a foreign private issuer to furnish a company press release. The filing states that on September 23, 2025, Nyxoah issued a press release, which is attached as Exhibit 99.1. The exhibit is being furnished rather than filed, meaning it is not subject to Section 18 liability and is not automatically incorporated into other Securities Act or Exchange Act filings unless specifically referenced.